Metformin in Pregnancy Study (MiPS): protocol for a systematic review with individual patient data meta-analysis.

Published on May 21, 2020in BMJ Open2.496
· DOI :10.1136/BMJOPEN-2020-036981
Aya Mousa15
Estimated H-index: 15
(Monash University, Clayton campus),
Tone Shetelig Løvvik3
Estimated H-index: 3
(NTNU: Norwegian University of Science and Technology)
+ 14 AuthorsHelena J. Teede74
Estimated H-index: 74
(Monash University, Clayton campus)
Introduction Gestational diabetes mellitus (GDM) is a common disorder of pregnancy and contributes to adverse pregnancy outcomes. Metformin is often used for the prevention and management of GDM; however, its use in pregnancy continues to be debated. The Metformin in Pregnancy Study aims to use individual patient data (IPD) meta-analysis to clarify the efficacy and safety of metformin use in pregnancy and to identify relevant knowledge gaps. Methods and analysis MEDLINE, EMBASE and all Evidence-Based Medicine will be systematically searched for randomised controlled trials (RCT) testing the efficacy of metformin compared with placebo, usual care or other interventions in pregnant women. Two independent reviewers will assess eligibility using prespecified criteria and will conduct data extraction and quality appraisal of eligible studies. Authors of included trials will be contacted and asked to contribute IPD. Primary outcomes include maternal glycaemic parameters and GDM, as well as neonatal hypoglycaemia, anthropometry and gestational age at delivery. Other adverse maternal, birth and neonatal outcomes will be assessed as secondary outcomes. IPD from these RCTs will be harmonised and a two-step meta-analytic approach will be used to determine the efficacy and safety of metformin in pregnancy, with a priori adjustment for covariates and subgroups to examine effect moderators of treatment outcomes. Sensitivity analyses will assess heterogeneity, risk of bias and the impact of trials which have not provided IPD. Ethics and dissemination All IPD will be deidentified and studies contributing IPD will have ethical approval from their respective local ethics committees. This study will provide robust evidence regarding the efficacy and safety of metformin use in pregnancy, and may identify subgroups of patients who may benefit most from this treatment modality. Findings will be published in peer-reviewed journals and disseminated at scientific meetings, providing much needed evidence to inform clinical and public health actions in this area.
📖 Papers frequently viewed together
5 Citations
20192.50BMJ Open
3 Citations
22 Citations
#1Julian P T Higgins (University of Cambridge)H-Index: 135
#2Sally Green (Cochrane Collaboration)H-Index: 66
The Cochrane Handbook for Systematic Reviews of Interventions is the official document that describes in detail the process of preparing and maintaining Cochrane systematic reviews on the effects of healthcare interventions.
10.8k Citations
#1Leon de Wit (UU: Utrecht University)H-Index: 2
#2Doortje Rademaker (UvA: University of Amsterdam)H-Index: 1
Last. Bas B. van RijnH-Index: 20
view all 66 authors...
Introduction In women with gestational diabetes mellitus (GDM) requiring pharmacotherapy, insulin was the established first-line treatment. More recently, oral glucose lowering drugs (OGLDs) have gained popularity as a patient-friendly, less expensive and safe alternative. Monotherapy with metformin or glibenclamide (glyburide) is incorporated in several international guidelines. In women who do not reach sufficient glucose control with OGLD monotherapy, usually insulin is added, either with or ...
2 CitationsSource
#1Tone Shetelig Løvvik (NTNU: Norwegian University of Science and Technology)H-Index: 3
#2Sven M. Carlsen (NTNU: Norwegian University of Science and Technology)H-Index: 26
Last. Eszter Vanky (NTNU: Norwegian University of Science and Technology)H-Index: 23
view all 19 authors...
Summary Background Women with polycystic ovary syndrome (PCOS) have an increased risk of pregnancy complications. Epi-analysis of two previous randomised controlled trials that compared metformin with placebo during pregnancy in women with PCOS showed a significant reduction in late miscarriages and preterm births in the metformin group. The aim of this third randomised trial (PregMet2) was to test the hypothesis that metformin prevents late miscarriage and preterm birth in women with PCOS. Meth...
36 CitationsSource
#1Jodie M Dodd (University of Adelaide)H-Index: 50
#2Jennie Louise (University of Adelaide)H-Index: 11
Last. William M. Hague (University of Adelaide)H-Index: 34
view all 7 authors...
Summary Background Maternal overweight and obesity are associated with well recognised pregnancy complications. Antenatal dietary and lifestyle interventions have a modest effect on gestational weight gain without affecting pregnancy outcomes. We aimed to assess the effects on maternal and infant outcomes of antenatal metformin given in addition to dietary and lifestyle advice among overweight and obese pregnant women. Methods GRoW was a multicentre, randomised, double-blind, placebo-controlled ...
29 CitationsSource
#1Linh Nguyen (Agency for Science, Technology and Research)H-Index: 9
#2Shiao-Yng Chan (Agency for Science, Technology and Research)H-Index: 14
Last. Adrian Kee Keong TeoH-Index: 18
view all 3 authors...
Abstract For more than 40 years, metformin has been used before and during pregnancy. However, it is important to note that metformin can cross the placenta and circulate in the developing foetus. Recent studies reported that the concentration of metformin in foetal cord blood ranges from half to nearly the same concentration as in the maternal plasma. Since metformin has anti-cell growth and pro-apoptotic effects, there are persistent concerns over the use of metformin in early pregnancy. Curre...
14 CitationsSource
#1Joanne Given (Ulster University)H-Index: 6
#2Maria Loane (Ulster University)H-Index: 54
Last. Helen Dolk (Ulster University)H-Index: 69
view all 14 authors...
Abstract Objective To investigate whether exposure to metformin during the first trimester of pregnancy, for diabetes or other indications, increases the risk of all or specific congenital anomalies. Design Population based exploratory case-control study using malformed controls. Cases of 29 specific subgroups of non-genetic anomalies, and all non-genetic anomalies combined, were compared with controls (all other non-genetic anomalies or genetic syndromes). Setting 11 EUROmediCAT European congen...
69 CitationsSource
#1E. Valdes (University of Chile)H-Index: 6
#2Álvaro Sepúlveda-Martínez (University of Chile)H-Index: 10
Last. Eduardo CuellarH-Index: 1
view all 7 authors...
Aim We aimed to assess the use of metformin (MTF) in the prevention of gestational diabetes mellitus (GDM) in patients with pregestational insulin resistance (PIR). Methods A double blind, multicenter, randomized trial was carried out in patients with a history of PIR and pregestational MTF treatment. Groups were allocated either to MTF 1700 mg/day or placebo. Patients were recruited between 12+0 and 15+6 gestational weeks, and treatment was extended until week 36. A multiple logistic regression...
11 CitationsSource
#1Hui-ling Liang (CSU: Central South University)H-Index: 4
#2Shujuan MaH-Index: 8
Last. Hongzhuan TanH-Index: 18
view all 4 authors...
AbstractBackground:The safety and efficacy of different drugs in treatment of gestational diabetes mellitus (GDM) patients who could not maintain normal glucose level only through diet and exercise remains to be debated. We performed this network meta-analysis (NAM) to compare and rank different ant
22 CitationsSource
#1Robert S. Lindsay (Glas.: University of Glasgow)H-Index: 80
#2Sharon T. Mackin (Glasgow Royal Infirmary)H-Index: 3
Last. Scott M. Nelson (Glasgow Royal Infirmary)H-Index: 73
view all 3 authors...
Personalised treatment that is uniquely tailored to an individual’s phenotype has become a key goal of clinical and pharmaceutical development across many, particularly chronic, diseases. For type 2 diabetes, the importance of the underlying clinical heterogeneity of the condition is emphasised and a range of treatments are now available, with personalised approaches being developed. While a close connection between risk factors for type 2 diabetes and gestational diabetes has long been acknowle...
6 CitationsSource
#1Robert S. Lindsay (BHF: British Heart Foundation)H-Index: 80
#2Mary R. Loeken (Joslin Diabetes Center)H-Index: 32
Metformin has been prescribed in pregnancy for over 40 years; for much of this time, use has been limited both in numbers and geographically, and the evidence base has been confined to observational studies. In early years, perceived safety concerns and lack of availability of the drug in many countries acted as a barrier to use. More recently, RCTs have begun to examine the role of metformin in pregnancy in much-needed detail. However, this evidence base has been interpreted differently in diff...
53 CitationsSource
Cited By3
#1Maria Jose Picon-Cesar (VU: Victoria University, Australia)H-Index: 1
#2María Molina-Vega (VU: Victoria University, Australia)H-Index: 5
Last. Stella González-Romero (UMA: University of Málaga)H-Index: 1
view all 10 authors...
Abstract Background Gestational diabetes not properly controlled with diet has been commonly treated with insulin. In recent years several studies have published that metformin can lead to, at least, similar obstetrical and perinatal outcomes as insulin. Nevertheless, not all clinical guidelines endorse its use, and clinical practice is heterogeneous. Objectives The aim of this study was to test if metformin could achieve the same glycemic control as insulin and similar obstetrical and perinatal...
2 CitationsSource
INTRODUCTION This review covers the current evidence regarding the use of metformin as a therapeutic intervention for optimizing pregnancy outcomes in women with polycystic ovary syndrome (PCOS). AREAS COVERED After searching Medline, Embase and CINAHL, all important large clinical trials and observational studies plus systematic reviews, meta-analyses and Cochrane reviews have been summarized here. The results have been compared to culminate in a thorough review and discussion on the use of met...
1 CitationsSource
#1Vincent L. Versace (Deakin University)H-Index: 18
#2Hannah Beks (Deakin University)H-Index: 4
Last. James Dunbar (Deakin University)H-Index: 29
view all 9 authors...
Women with a history of gestational diabetes mellitus (GDM) are at greater risk of developing type 2 diabetes mellitus (T2DM) when compared with women who have not had GDM. To delay or prevent T2DM, guidelines recommend regular screening in the primary care setting and lifestyle interventions that are largely focused on dietary and physical activity modifications. As the postpartum period can be challenging for women, uptake and engagement in screening and lifestyle interventions have been poor....